Management challenges of Rabson Mendenhall syndrome in a resource limited country: a case report

J Pediatr Endocrinol Metab. 2022 Sep 16;35(11):1429-1432. doi: 10.1515/jpem-2022-0214. Print 2022 Nov 25.

Abstract

Objectives: Rabson Mendenhall syndrome (RMS) is a rare form of insulin resistance syndrome caused by insulin receptor mutation. In term of severity, it lies at an intermediate point on spectrum of insulin resistance with Donohue syndrome flanking the severe and Type A insulin resistance at the mild end. We are reporting a 3.5-month-old boy with RMS along with its management challenges in a resource limited country.

Case presentation: An infant presented at 3.5-month of an age with failure to thrive and fluctuating blood glucose level (hyperglycaemia and hypoglycaemia) along with clinical features of insulin resistance. He was found to have raised HbA1C, high insulin and C peptide level and a homozygous mutation in INSR gene c.1049C>T, (p.Ser350 Leu) confirming the diagnosis of RMS. He was managed with long-acting insulin (Detemir) along with frequent feeding.

Conclusions: RMS in resource limited countries could be managed with frequent feeding along with insulin. Early diagnosis and management can improve long term outcome.

Keywords: Donohue syndrome; Rabson Mendenhall syndrome; insulin resistance syndrome; type A insulin resistance.

Publication types

  • Case Reports

MeSH terms

  • Donohue Syndrome* / genetics
  • Humans
  • Infant
  • Insulin / genetics
  • Insulin Resistance* / genetics
  • Male
  • Mutation
  • Receptor, Insulin / genetics

Substances

  • Receptor, Insulin
  • Insulin